The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products. It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.
Sofia, Bulgaria, August 7, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 6, 2025 the Company sold 6 000 (six thousand) repurchased own shares representing 0.001% of the share capital of the Company, at a total value of BGN 14 580.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.
Sofia, Bulgaria, August 6, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 5, 2025 the Company sold 3 831 544 (three million eight hundred thirty-one thousand five hundred forty-four) repurchased own shares representing 0.71% of the share capital of the Company, at a total value of BGN 9 311 051.92 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.
Sofia, Bulgaria, August 6, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 4, 2025 the Company sold 770 286 (seven hundred thousand two hundred eighty-six) repurchased own shares representing 0.14% of the share capital of the Company, at a total value of BGN 1 871 797.84 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.
Sofia, Bulgaria, August 5, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) corrects the text of the following notifications regarding sold repurchased shares due to a technical mistake as follows:
In notification of sale of treasury shares as of July 31, 2025:
The text:
“The total number of treasury shares after this transaction is 26 060 100 representing 4.83% of the share capital of the Company.”
Sofia, Bulgaria, August 4, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 1, 2025 the Company sold 10 500 (ten thousand five hundred) repurchased own shares representing 0.002% of the share capital of the Company, at a total value of BGN 25 625.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.44.
Sofia, Bulgaria, August 1, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 31, 2025 the Company sold 2 400 (two thousand four hundred) repurchased own shares representing 0.0004% of the share capital of the Company, at a total value of BGN 5 778.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.41.
Sofia, Bulgaria, July 31, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 30, 2025 the Company sold 28 500 (twenty-eight thousand five hundred) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 68 969.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.42.
